COVID-19
RESEARCH AND ENGAGEMENT PROJECTS PORTFOLIO

Projects in Progress & Outputs | August 31, 2021
# Table of Content

## Introduction

1. Tracking all-cause mortality at the epicentre of Indonesia’s COVID-19 epidemic (TREMOR)
2. Natural history of SARS-CoV-2 in comparison to influenza A virus
3. Impact of the COVID-19 epidemic on TB, HIV, and childhood vaccination programmes in Indonesia
4. Strengthening Preparedness in the Asia-Pacific Region through Knowledge – SPARK
5. Covid-19 ICU burden
6. A web-based application on contact tracing questionnaire
7. Characterising the distribution of incubation time and latency time
8. The probability to remain asymptomatic and its dependence on age, sex and the presence of comorbidities
10. Optimizing the timing of the second dose of vaccine shot
11. Evaluating mortality data to capture the dynamics of COVID-19 in Java, Indonesia

## Epidemiology & Modelling Studies

---

1. Tracking all-cause mortality at the epicentre of Indonesia’s COVID-19 epidemic (TREMOR)
2. Natural history of SARS-CoV-2 in comparison to influenza A virus
3. Impact of the COVID-19 epidemic on TB, HIV, and childhood vaccination programmes in Indonesia
4. Strengthening Preparedness in the Asia-Pacific Region through Knowledge – SPARK
5. Covid-19 ICU burden
6. A web-based application on contact tracing questionnaire
7. Characterising the distribution of incubation time and latency time
8. The probability to remain asymptomatic and its dependence on age, sex and the presence of comorbidities
10. Optimizing the timing of the second dose of vaccine shot
11. Evaluating mortality data to capture the dynamics of COVID-19 in Java, Indonesia

## Social Science Studies

---

1. COVID-19 Social Science and Public Engagement Action Research in Viet Nam, Indonesia and Nepal

## Public & Community Engagement

---

1. Public and community engagement response to Covid-19
2. Combating Covid-19-related disinformation and fake news

## Policy Engagement

---

1. Covid-19 and the gendered research gap
2. Engaging with policymakers in the COVID-19 pandemic through an Outbreak Advisory Board

## Our People

---

1. The RECOVERY Trial – A Randomised Evaluation of COVID-19 Therapy
2. The COPCOV Study
3. Prediction of respiratory failure in COVID-19 infection and understanding pathophysiological mechanisms
4. ISARIC Study: The natural history of SARS-CoV-2 infection in Viet Nam
5. Clinical characteristics, management and disease outcomes of COVID-19 patients in Indonesia
6. The impact of Covid-19 on pregnancy care and outcomes (CovPreg)
7. Real-world assessment of the immunogenicity and effectiveness of COVID-19 vaccines in Indonesia (INVITE Study)
8. Advanced analytics of Covid-19 patient data to better define infection and outcomes
9. Evaluating clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia
10. Validation of SARS-CoV-2 diagnosis with RT-LAMP on FTA filter paper for remote sites in Indonesia
11. Establishing the Southeast Asia Serological Surveillance Network (SASSNet) in Indonesia & Viet Nam
12. Consortium for Surveillance of SARS-CoV-2 Sequence and Structure in LMICs
13. Immunogenicity and safety of COVID-19 vaccine in Vietnamese healthcare workers
14. Enhancing the utility of SARS-CoV-2 antibody rapid diagnostic tests (RDTs) for disease surveillance.
INTRODUCTION

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and its disease, COVID-19, have caused unprecedented disruption globally since they were first described in China in December 2019. The OUCRU programme has felt the full force of that disruption, with severe lockdowns and waves of infection experienced repeatedly over the last 18 months in Viet Nam, Indonesia and Nepal. However, alongside the disruption has come opportunity, particularly the opportunity to conduct research that helps us understand the medical and social impact of the pandemic and improve the ways we control and treat the virus.

The entire OUCRU programme should be enormously proud of the way it has responded to the pandemic. The virus has brought us together. We have supported one another through many difficult periods when the virus seemed to threaten every aspect of our life and work, and we have found new ways to communicate and collaborate. The consequent research has been remarkable, not least because its conception and conduct has been in some of the most difficult circumstances any of us have ever experienced. We have addressed almost every important aspect of the pandemic, from its societal impact to viral genomic surveillance and COVID-19 therapy. Our work has fostered new collaborations with respective governments and their institutions that have ensured our research is relevant and impactful. These collaborations will have a lasting effect on OUCRU’s standing and future work within the region.

Sadly, the pandemic still has a long way to run. Vaccination in low- and middle-income countries lags behind the wealthier regions of the world – a major current failure of ‘global health’ – and the research questions are many and pressing. Here, we provide an overview of OUCRU’s research response – it gives a snapshot of the work conducted across the programme and one we will continually update.

Of course, none of the work described would be possible without our key partners – The Hospital for Tropical Diseases in Ho Chi Minh City, the National Hospital for Tropical Diseases and the National Institute of Hygiene And Epidemiology in Hanoi, Patan Academy of Health Sciences in Nepal, the Eijkman Institute and the University of Indonesia in Indonesia, and the University of Oxford, UK – and without the support from our funders, in particular the Wellcome Trust.

Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APF</td>
<td>Armed Police Force Hospital, Nepal</td>
</tr>
<tr>
<td>BPKIHS</td>
<td>B.P. Koirala Institute of Health Sciences, Nepal</td>
</tr>
<tr>
<td>CDC</td>
<td>Centre for Disease Control</td>
</tr>
<tr>
<td>DFAT</td>
<td>Australian Department of Foreign Affairs and Trade</td>
</tr>
<tr>
<td>EOCCRU</td>
<td>Eijkman–Oxford Clinical Research Unit</td>
</tr>
<tr>
<td>FKUI</td>
<td>Fakultas Kedokteran Universitas Indonesia</td>
</tr>
<tr>
<td>HTD</td>
<td>Hospital For Tropical Diseases, Ho Chi Minh City, Viet Nam</td>
</tr>
<tr>
<td>ICU</td>
<td>Intensive care unit</td>
</tr>
<tr>
<td>IOCRUL</td>
<td>Universities of Indonesia and Oxford Clinical Research Laboratory</td>
</tr>
<tr>
<td>LMICs</td>
<td>Low- and middle-income countries</td>
</tr>
<tr>
<td>NHRC</td>
<td>Nepal Health Research Council</td>
</tr>
<tr>
<td>NHTD</td>
<td>Viet Nam National Hospital For Tropical Diseases, Hanoi</td>
</tr>
<tr>
<td>NIH CEIRS</td>
<td>US National Institutes of Health, Centers of Excellence for Influenza Research</td>
</tr>
<tr>
<td>NIHIE</td>
<td>Viet Nam National Institute of Hygiene and Epidemiology</td>
</tr>
<tr>
<td>NIHR</td>
<td>UK National Institute for Health Research</td>
</tr>
<tr>
<td>OUCRU</td>
<td>Oxford University Clinical Research Unit</td>
</tr>
<tr>
<td>OxTREC</td>
<td>Oxford Tropical Research Ethics Committee</td>
</tr>
<tr>
<td>PAHS</td>
<td>Patan Academy of Health Sciences, Nepal</td>
</tr>
<tr>
<td>PBMC</td>
<td>Peripheral blood mononuclear cells</td>
</tr>
<tr>
<td>PCR Test</td>
<td>Polymerase Chain Reaction (PCR) test</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RSSBD</td>
<td>Rumah Sakit Umum Daerah Sumba Barat Daya Hospital, Indonesia</td>
</tr>
<tr>
<td>STID</td>
<td>Sukraraj Tropical and Infectious Disease Hospital, Nepal</td>
</tr>
</tbody>
</table>
About Us

The Oxford University Clinical Research Unit (OUCRU) is a large-scale clinical and public health research unit with site offices in Viet Nam, Indonesia, and Nepal.

Part of the Centre for Tropical Medicine and Global Health at the University of Oxford (UK), OUCRU was first established in Ho Chi Minh City in 1991, hosted by the Hospital for Tropical Diseases (HTD), Viet Nam. In 2003, OUCRU-NP was established in Kathmandu, Nepal, hosted by Patan Hospital and the Patan Academy of Health Sciences. OUCRU Hanoi was established in 2006 in partnership with the National Hospital for Tropical Diseases (NHTD) and the National Institute of Hygiene and Epidemiology (NIHE), Viet Nam. In 2008, the Eijkman-Oxford Clinical Research Unit (EOCRU) was established in Jakarta, Indonesia, in partnership with the Eijkman Institute for Molecular Biology and Faculty of Medicine University of Indonesia.

Our vision is to have a local, regional and global impact on health by leading a locally-driven research programme on infectious diseases in Southeast Asia.

Our research programme covers clinical and laboratory research with hospital and community-based patient populations, including epidemiology, immunology, host and pathogen genetics, molecular biology, microbiology and virology, mathematical modelling, bioinformatics, biostatistics, and social science. This work is supported by an extensive clinical trials unit and data management centre compliant with national and international regulations and comprehensive management, finance, public engagement, and administrative support offices.

OUCRU receives considerable support from Wellcome as part of the Africa and Asia Programmes. Together with our partners, we have led a highly successful effort in enhancing the infrastructure and capacity to perform clinical trials and basic scientific research in Viet Nam, Indonesia, and Nepal.

Website: www.oucru.org
COVID-19 SNAPSHoT

On March 11, 2020, when WHO declared the COVID-19 outbreak a pandemic, countries in WHO South Asia and Southeast Asia Region were either responding to their first cases of importation or cluster of cases or keeping a strict vigil against the importation of the new coronavirus. Now, more than 18 months later, the pandemic is still raging on, with ongoing waves of infection sweeping through countries across the world.

By August 31, 2021, a total of 217.7 million cases3 had been recorded worldwide, and 4.5 million people had died.

After a long period of relative containment, Viet Nam is now experiencing its first major wave of nationwide infections, starting end of April, with now (August 29, 2021) more than 435,000 cases and nearly 11,000 deaths reported. At the time of this writing, most of Viet Nam’s population, including the capital city of Hanoi4 and the heavily populated Mekong Delta region5, is in lockdown due to a surge of cases nationwide.

Meanwhile, in Indonesia, the fourth most populous nation in the world, nearly 4.1 million cases had been detected, and nearly 132,000 people had died (data reported on August 29, 2021).

Nepal is experiencing a second wave, with over 759,000 cases reported as of August 29, 2021. Nearly 11,000 people have died.

Time of data: August 29, 2021
For updated Covid-19 data, visit Our World in Data6
For more information, refer to weekly Covid-19 Situation Reports by WHO:
For a full list of SARS-CoV-2 Variants of Interest (VOIs) and Variants of Concern (VOCs), visit: https://bit.ly/COVIDVidants

Source: Our World in Data6

<table>
<thead>
<tr>
<th>Country</th>
<th>Total Confirmed Cases (per million people)</th>
<th>Total Deaths (per million people)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viet Nam</td>
<td>4,434</td>
<td>110</td>
</tr>
<tr>
<td>Indonesia</td>
<td>14,741</td>
<td>477</td>
</tr>
<tr>
<td>Nepal</td>
<td>25,585</td>
<td>361</td>
</tr>
</tbody>
</table>

Variants
During late 2020, the emergence of SARS-CoV-2 variants that posed an increased risk to global public health prompted the characterisation of specific Variants of Interest (VOIs) and Variants of Concern (VOCs) in order to prioritise global monitoring and research, and ultimately to inform the ongoing response to the COVID-19 pandemic.

The Delta variant (Pango lineages B.1.617.2; AY.1; AY.2), first documented in India in October 2020, is responsible for the current surge of cases in most countries in South and Southeast Asia, including Viet Nam, Indonesia, and Nepal.

Vaccines
As of June 22, 2021, at least 13 different vaccines (across four platforms) have been approved by WHO and administered worldwide.

In Viet Nam, people 18 or older6 (around 68 million people8) are eligible to get the vaccine. As of August 30, 25 per cent of Viet Nam’s eligible population (17.19 million people) have received at least one dose of the vaccine, and 3.7 per cent (2.52 million people) have been fully vaccinated.

Indonesia started vaccinating its adult population (173 million people9 over 18) at the beginning of the year. As of August 30, 2021, around 36 per cent of its eligible population (62.62 million people) have received at least one dose of the COVID-19 vaccine, and 20.5 per cent (35.53 million people) have been fully vaccinated. The national vaccine rollout is primarily based on Sinovac-CoronaVac and AstraZeneca, with smaller batches of other vaccines becoming available.

On July 10, Indonesia announced its plan to give nearly 1.5 million healthcare workers a third shot of Moderna’s mRNA vaccine to increase the protection in response to a new outbreak in the country.

Nepal launched its vaccination drive on January 2710, with an eligible population of 21.6 million11 people. As of August 30, about 25 per cent of the country’s adult population (5.32 million people) have received at least one dose, and about 20 per cent (around 4.4 million people) have been fully vaccinated.
The RECOVERY Trial – A Randomised Evaluation of COVID-19 Therapy

Principal Investigators
OUCRU: Jeremy Day
EOCRU: Raph Hamers
OUCRU-NP: Buddha Basnyat

Locations of the study
Nepal, Indonesia, Viet Nam (HCMC and Hanoi)

More information
https://www.recoverytrial.net/

Funders:
This trial is supported by grants to the University of Oxford from the National Institute for Health Research (NIHR), UK Research and Innovation, and Wellcome, and by core funding provided by the Bill and Melinda Gates Foundation, the Foreign, Commonwealth & Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Oxford Biomedical Research Centre, NIHR Clinical Trials Unit Support Funding, and Wellcome Trust.

Aims:
This international clinical trial aims to identify treatments that reduce the risk of death in patients hospitalised with suspected or confirmed COVID–19. It is a large multicenter trial recruiting in hospitals in the United Kingdom, Indonesia, Nepal, Viet Nam and Ghana.

Study Design:
Well–designed, pragmatic, and easy to implement clinical trials are key to generating the evidence needed to best manage pandemic diseases, which occur essentially in emergency situations. The RECOVERY trial sets this paradigm. It is a large open–label factorial designed platform trial that enables the simultaneous testing of multiple different treatments. As particular treatments are found to be effective or ineffective, they are dropped from the trial and should form part of the standard of care.

The study is designed to have high power to deliver precise estimates of the effect of particular treatments on the risk of death. New treatment interventions are added to the trial as evidence emerges from small–scale studies of their possible value. While originally based in the UK, the extension of the RECOVERY trial to international sites, building upon well–established clinical research networks and collaborations, will ensure that the results of the trial have global relevance.
RECOVERY in Nepal

RECOVERY in Nepal is being led by the Nepal Health Research Council (NHRC) in collaboration with OUCRU-Nepal. There are currently three active sites in Nepal: Sukraraj Tropical and Infectious Disease Hospital (STIDH), Armed Police Force (APF) hospital and Nepal Police Hospital (NPH).

The site Principal Investigator for STIDH, APF Hospital and NPH are Dr Anup Bastola, Chief consultant of Tropical Medicine, Dr Roshan Kumar Jha, Consultant physician and Dr Damodar Paudel, Head of Internal Medicine Department, respectively.

Prof Buddha Basnyat from OUCRU-Nepal and Dr Pradip Gyanwali from NHRC are the country investigators for this trial.

About the Nepal site:
Sukraraj Tropical and Infectious Disease Hospital (STIDH) is the only Infectious & Tropical Disease Hospital established in 1933 in Kathmandu, Nepal. This is the national referral hospital with a capacity of 100 beds inpatient service. It receives patients from all over the country and referred patients from the Valley hospitals. This is one of the main hospitals in Kathmandu valley where patients with COVID-19 are being treated.

Armed Police Force (APF) hospital is a 200-bed government hospital that was dedicated as an anti-coronavirus dedicated facility by the Ministry of Health, Nepal. Recently another police hospital (Nepal Police Hospital) has also been added for enrolment of patients. This is also a government hospital which has a capacity of 200 beds.

Outputs to Date:
Having enrolled more than 41,500 patients to date, RECOVERY has provided precise data demonstrating the efficacy of dexamethasone, tocilizumab, and a cocktail of CoV antibodies (Regeneron) in reducing the risk of death in hospitalized patients, and that hydroxychloroquine, azithromycin, lopinavir–ritonavir, aspirin, colchicine, and convalescent plasma are ineffective. These results have influenced World Health Organisation and national guidelines for the treatment of COVID-19. Current treatments undergoing evaluation include high dose corticosteroids and empagliflozin.

Publications:

RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. [Internet] 2021; Available from: https://doi.org/10.1011/2021.06.15.21255852


RECOVERY in Indonesia

RECOVERY in Indonesia will be hosted and led by the Faculty of Medicine, University of Indonesia and supported by the Universities of Indonesia and Oxford Clinical Research Laboratory (OCRL), a joint facility established in 2017 on the faculty's campus in Central Jakarta, that serves as a hub to support clinical trials, education and public engagement.

The study is being managed by Dr Erni Nelwan (Faculty of Medicine University of Indonesia, FKUI) as the country Principal Investigator, Prof Raph Hamers (Oxford University, based at FKUI) as the country’s responsible investigator of the trial, and Dr Mutia Radharjani, as the Head of the Clinical Research Support Unit at the Eijkman-Oxford Clinical Research Unit (EOCRU).

The trial is recruiting at Martha Friska Hospital, Medan; Metropolitan Medical Centre, Jakarta; Hasan Sadikin Hospital, Bandung; UNAIR hospital, Surabaya; Kandou Hospital, Manado; and other potential sites.

RECOVERY in Viet Nam

The National Hospital for Tropical Diseases (NHTD), Ha Noi, is a tertiary care centre for infectious diseases in northern Viet Nam. Unlike most hospitals, NHTD is a specialist hospital under the direct supervision of the Ministry of Health.

The Hospital for Tropical Diseases (HTD), Ho Chi Minh City, is the referral hospital for infectious diseases for all of southern Viet Nam.

Output to Date:
The introduction of remdesivir and tocilizumab for COVID-19 was a major milestone for global COVID-19 research. This trial will be hosted and led by the University of Indonesia and Oxford Clinical Research Laboratory (OCRL), a joint facility established in 2017 on the faculty's campus in Central Jakarta, that serves as a hub to support clinical trials, education and public engagement.

The study is being managed by Dr Erni Nelwan (Faculty of Medicine University of Indonesia, FKUI) as the country Principal Investigator, Prof Raph Hamers (Oxford University, based at FKUI) as the country’s responsible investigator of the trial, and Dr Mutia Radharjani, as the Head of the Clinical Research Support Unit at the Eijkman-Oxford Clinical Research Unit (EOCRU).

The trial is recruiting at Martha Friska Hospital, Medan; Metropolitan Medical Centre, Jakarta; Hasan Sadikin Hospital, Bandung; UNAIR hospital, Surabaya; Kandou Hospital, Manado; and other potential sites.

RECOVERY in Indonesia

RECOVERY in Indonesia will be hosted and led by the Faculty of Medicine, University of Indonesia and supported by the Universities of Indonesia and Oxford Clinical Research Laboratory (OCRL), a joint facility established in 2017 on the faculty's campus in Central Jakarta, that serves as a hub to support clinical trials, education and public engagement.

The study is being managed by Dr Erni Nelwan (Faculty of Medicine University of Indonesia, FKUI) as the country Principal Investigator, Prof Raph Hamers (Oxford University, based at FKUI) as the country’s responsible investigator of the trial, and Dr Mutia Radharjani, as the Head of the Clinical Research Support Unit at the Eijkman-Oxford Clinical Research Unit (EOCRU).

The trial is recruiting at Martha Friska Hospital, Medan; Metropolitan Medical Centre, Jakarta; Hasan Sadikin Hospital, Bandung; UNAIR hospital, Surabaya; Kandou Hospital, Manado; and other potential sites.

RECOVERY in Viet Nam

The National Hospital for Tropical Diseases (NHTD), Ha Noi, is a tertiary care centre for infectious diseases in northern Viet Nam. Unlike most hospitals, NHTD is a specialist hospital under the direct supervision of the Ministry of Health.

The Hospital for Tropical Diseases (HTD), Ho Chi Minh City, is the referral hospital for infectious diseases for all of southern Viet Nam.

Output to Date:
The introduction of remdesivir and tocilizumab for COVID-19 was a major milestone for global COVID-19 research. This trial will be hosted and led by the University of Indonesia and Oxford Clinical Research Laboratory (OCRL), a joint facility established in 2017 on the faculty's campus in Central Jakarta, that serves as a hub to support clinical trials, education and public engagement.

The study is being managed by Dr Erni Nelwan (Faculty of Medicine University of Indonesia, FKUI) as the country Principal Investigator, Prof Raph Hamers (Oxford University, based at FKUI) as the country’s responsible investigator of the trial, and Dr Mutia Radharjani, as the Head of the Clinical Research Support Unit at the Eijkman-Oxford Clinical Research Unit (EOCRU).

The trial is recruiting at Martha Friska Hospital, Medan; Metropolitan Medical Centre, Jakarta; Hasan Sadikin Hospital, Bandung; UNAIR hospital, Surabaya; Kandou Hospital, Manado; and other potential sites.

RECOVERY in Indonesia

RECOVERY in Indonesia will be hosted and led by the Faculty of Medicine, University of Indonesia and supported by the Universities of Indonesia and Oxford Clinical Research Laboratory (OCRL), a joint facility established in 2017 on the faculty's campus in Central Jakarta, that serves as a hub to support clinical trials, education and public engagement.

The study is being managed by Dr Erni Nelwan (Faculty of Medicine University of Indonesia, FKUI) as the country Principal Investigator, Prof Raph Hamers (Oxford University, based at FKUI) as the country’s responsible investigator of the trial, and Dr Mutia Radharjani, as the Head of the Clinical Research Support Unit at the Eijkman-Oxford Clinical Research Unit (EOCRU).

The trial is recruiting at Martha Friska Hospital, Medan; Metropolitan Medical Centre, Jakarta; Hasan Sadikin Hospital, Bandung; UNAIR hospital, Surabaya; Kandou Hospital, Manado; and other potential sites.
The COPCOV Study

**Funders**
- Bill & Melinda Gates Foundation
- Wellcome Trust
- MasterCard
- Therapeutics Accelerator

**Principal Investigator**
- Nick White (MORU)

**EOCRU PI**
- Raph Hamers

**OUCRU-NP PI**
- Buddha Basnyat

**Location of activity**
- Nepal and Indonesia
- Activity suspended in Viet Nam due to low patient numbers.

**Website**
- www.tropmedres.ac/ covid-19/copcov

**Background:**
COVID-19 has caused nearly 4.5 million deaths. Although vaccines are being deployed, the timelines for widespread roll-out are likely to be lengthy, particularly in areas where health systems are most fragile. Many experts anticipate that smaller outbreaks may occur in the future and that the disease will likely stay with us for a considerable time.

Chloroquine/ hydroxychloroquine have been in constant use for more than 60 years. They are cheap, safe, well-tolerated and, importantly, available now. However, we still do not know, a year after the emergence of COVID-19, whether they can prevent the infection. These drugs could still be of benefit while we wait for the world’s population to be vaccinated. Chloroquine/ hydroxychloroquine may also be beneficial in future pandemics, where vaccines would not be instantly available, or if vaccines became ineffective in the current pandemic.

Front-line healthcare workers and other high-risk individuals are at increased risk of infection. It is crucial that they are protected against the disease. Adequate personal protection is key, but additional interventions could further lower the risk of infection. There are currently no drugs for the prevention of COVID-19. The World Health Organization recommends that outside the clinical trial setting, we should not give healthcare workers any drugs claiming to prevent COVID-19 before we know that they are safe and effective.

**About the study:**
COPCOV is a randomised, placebo-controlled pre-exposure prophylaxis study to determine whether chloroquine or hydroxychloroquine prevents coronavirus disease (COVID-19).

The COPCOV study will enrol 40,000+ vital frontline healthcare workers and staff who have close contact with COVID-19 patients to determine whether chloroquine or hydroxychloroquine effectively prevents or reduces the severity of COVID-19 infections. We expect to have preliminary results as to whether chloroquine or hydroxychloroquine can prevent COVID-19 after mid-2021.

**COPCOV in Nepal**

The trial preparation was put on hold in Nepal due to the country’s mass vaccination of healthcare workers. But it now has started enrollment and randomization in the community adjoining the B.P. Koirala Institute of Health Sciences (BPKIHS) after the successful amendment of the protocol, which now includes the general public who are at risk to contract COVID-19.

**Description of the team:**
This study is being managed by Dr Suchita Shrestha, a Medical doctor and an MPH graduate from Mahidol University, Thailand.

Dr Sanjib Kumar Sharma is the site PI and will be supervising the study at BPKIHS, Dharan. He is the head of the Department of Internal Medicine in Nepal. He has been involved in various multicentre research projects related to chronic kidney disease, diabetes, hypertension, snake bites etc. and has published more than 120 articles in national and international journals in the related fields. He is also the key personnel directly involved in the management of COVID-19 patients at BPKIHS, Dharan, Nepal.

**About the Nepal site:**
B.P. Koirala Institute of Health Sciences (BPKIHS) was established on January 18, 1993, and subsequently upgraded as an Autonomous Health Sciences University on October 28, 1998, with a mandate to work towards developing a socially responsible and competent health workforce, providing health care and engaging in health research. BPKIHS is located in Eastern Nepal & it has extended its continued health services through teaching district concepts to Primary Health Care Centers, District Hospitals and Zonal Hospitals in six districts of the region.

This Institute is envisaged as one of the finest examples of Indo–Nepal Cooperation. This University is aptly named after Bisheshwar Prasad Koirala, Nepal’s visionary leader in social upliftment and a firm believer of National Reconciliation and National Integration. Candidates from disadvantaged groups are given opportunities for admission in most of the academic programmes. While selecting candidates for postgraduate studies, the Institute has given due recognition to those medical officers who have worked in the primary health centres and district hospitals.

**Outputs to date:**


Observational clinical studies

Prediction of respiratory failure in COVID-19 infection and understanding pathophysiological mechanisms

**Funder**
University of Oxford

**Principal Investigator**
Sophie Yacoub

**Locations of activity**
Hanoi, Ho Chi Minh City, and Cu Chi, Viet Nam and Jakarta, Indonesia

**Background:**
In this observational study, our primary aim is to utilise the expertise we have developed in OUCRU Viet Nam to develop dynamic models that predict disease progression using real-time, longitudinal clinico-physiological data and specific blood biomarkers. Achieving this requires research in early infection and across the disease severity spectrum. In many countries, this is difficult due to the high burden of severe cases. In Viet Nam, the early identification of SARS-CoV-2 infections is routine due to a highly efficient test, trace and quarantine system.

At OUCRU Viet Nam, in collaboration with Oxford University, we are using point-of-care ultrasound and physiological monitoring via simple, low-cost wearable devices to develop artificial intelligence (AI) systems to better manage critically ill patients.

In this project, we intend to use conventional statistical techniques and AI to develop dynamic predictive models that will enable the identification of patients at risk of disease progression in COVID-19. We will build on our expertise using data from wearable devices, point-of-care heart and lung ultrasound, and specific blood biomarkers.

**Status:**
This study is currently recruiting in two sites in Ho Chi Minh City (Hospital for Tropical Diseases and Cu Chi Hospital) as well as in the National Hospital for Tropical Diseases in Hanoi and the Pasar Minggu Hospital in Jakarta, Indonesia.
Background: Most clinical research to date has been focusing on COVID-19 patients with moderately severe to severe disease because these are groups of patients that are admitted to hospitals for management worldwide. As a consequence, little is known about the natural history and transmission potential of completely asymptomatic and very mild infection with SARS-CoV-2.

We are in a unique position to study the natural history of SARS-CoV-2 infection due to the strict isolation, quarantine and contract tracing protocols enacted in Viet Nam. We are able, therefore, to recruit patients into our studies at all stages of infection, including pre- and asymptomatic carriers.

We also aim to evaluate the utility potential of wearable devices in monitoring COVID-19 patients remotely, thereby reducing the risk of transmission for healthcare workers.

Importance: Our aim is to better understand the natural history of the infection. This is important to inform the development of intervention strategies and is highly relevant for the current global response to the ongoing COVID-19 pandemic.

Objectives:
1. To describe the clinical, laboratory and virological characteristics of SARS-CoV-2 infection;
2. To study the immune responses in SARS-CoV-2 infected patients;
3. To identify potential protein markers that can predict severe disease;
4. To unravel the evolutionary history of SARS-CoV-2 at both within the human host and population-level;
5. To evaluate the utility potential of rapid antigen tests for the diagnostics and management of COVID-19 patients;
6. To develop and sustain a research platform at key institutes and hospitals in Viet Nam to enable the country to rapidly respond to emerging infection outbreaks in the future.

Outputs to date:


Nguyen Van Vinh Chau, Nguyen Tri Dung, Geskus Ronald et al. Proactive response and innovative approaches to SARS-CoV-2 in Viet Nam. [Internet]. 2021; Available from: http://dx.doi.org/10.1136/bmjinnov-2021-000712

Clinical characteristics, management and disease outcomes of COVID-19 patients in Indonesia: Clinical Characterisation Protocol (INACO study)

Background:
The global COVID-19/SARS-CoV-2 pandemic disproportionately affects low- and middle-income countries (LMICs), but rigorous research of its clinical management and consequences in those settings is lacking. With the fourth-largest population (270 million) globally, Indonesia is facing tremendous challenges, particularly in Jakarta and other hot zones, with the highest death toll in the region.

In 2021, the pandemic shows no sign of slowing. Systematic approaches are urgently needed to “learn-as-we-go” by characterising clinical patterns, management and outcomes of hospitalised COVID-19 patients, analysed in an international context, to improve the constantly evolving national response.

The project accrues a prospective observational cohort of hospitalised COVID-19 patients in multiple hospitals in Jakarta and Medan, with additional sites being added in other cities in Indonesia, to generate this critically needed evidence. This work also establishes a research platform for ancillary studies of disease mechanisms and therapeutic intervention studies, including the use of wearable devices for patient monitoring, inflammation markers, and SARS-CoV-2 genomic surveillance.

Objectives:
1. To describe the clinical patterns, severity, and current management of COVID-19 patients, estimate the disease outcomes, and identify associated factors in Indonesia;
2. To inform local clinical practice and national policy based on this evidence and identify specific gaps in care;
3. To establish a COVID-19 clinical research platform for studies and trials.

The impact of Covid-19 on pregnancy care and outcomes (CovPreg)

Funder
OUCRU (Wellcome Funding)

Principal Investigator
Anuraj Shankar

Partner PIs
Dr. Rina Agustina (Faculty of Medicine University of Indonesia);
Ms. Annisa Dwi Utami (Summit Institute for Development)

Collaborators
Davrina Rianda (Faculty of Medicine University of Indonesia);
Yuni Dwi Setiyawati (Summit Institute for Development);
 Jakarta Health Office;
 District Health Office of Magelang, Banggai and East Lombok;
 University of Mataram School of Medicine.

Study locations
Jakarta, Districts of Magelang, Banggai, East Lombok, Indonesia

Primary objectives:
1. Document gaps and impact of changes in antenatal care (ANC), delivery, and post-natal care (PNC) due to health system changes during the Covid-19 pandemic in Indonesia.
   - Estimate gaps in ANC, delivery, and PNC due to Covid-19;
   - Estimate the impact of care gaps on maternal and neonatal health: pregnancy weight gain, blood pressure, haemoglobin level, blood sugar, delivery care, gestational age at birth, birth weight;
2. Estimate the excess morbidity and mortality among pregnant women and newborns due to maternal exposure or infection with SARS-CoV-2.

Importance:
Longitudinal analysis of maternal care for ~4000 women before and after the pandemic indicates ~40% reduction in overall ANC, with the most significant reductions in ANC2 and ANC3. Longitudinal follow-up of 1100 women under routine ANC care indicates ~2% of women are swab positive and asymptomatic at the first ANC visit, with ~32% being antibody positive; and ~34% becoming antibody-positive during pregnancy. Associations with birth weight, preterm birth and other pregnancy-related morbidities are underway. The goal of the work is to guide targeted strengthening of specific high impact components of maternal care during the pandemic and to define priority for resources to mitigate the impact of SARS-CoV-2, such as maternal vaccination.
Real-world assessment of the immunogenicity and effectiveness of COVID-19 vaccines in Indonesia (INVITE Study)

Principal Investigator
Raph Hamers

Partner PI
Dr Erni Nelwan

Location of activity
Hospitals and primary health centres in Jakarta, Indonesia

Collaborators
Dwi Utomo,
Pasar Minggu Hospital;
Robert Sinto,
Pelni Hospital;
Jakarta Health Office.

Background:
The unprecedented speed with which COVID-19 vaccines have been developed and approved represents a major scientific achievement, and vaccine–induced population immunity is a key global strategy to control the COVID-19 pandemic. There are still many “real-world” knowledge gaps on vaccine–induced immune responses, correlates of protection and temporal changes, the clinical impact of breakthrough infections, effectiveness and reactogenicity of (heterologous) vaccine boosters. More research is warranted to understand vaccine–induced humoral and cellular immunity to SARS-CoV-2, defining detailed targets of humoral and cellular immune responses at the epitope level, characterising the B-cell receptor and T-cell receptor repertoire elicited by infection or vaccination, and establishing the long-term durability and maintenance, of protective immunity after infection or vaccination. This is particularly true for the widely used inactivated whole-virus vaccines, such as Sinovac/CoronaVac and Sinopharm, being rolled out in many countries worldwide, including Indonesia, a populous middle-income country and one of the COVID-19 epicentres.

This research project offers a unique window of opportunity for research and learning to leverage several observational patient cohorts in Indonesian populations to conduct real-world assessments of COVID-19 vaccinations as they are rolled out to inform optimal vaccination strategies in the face of emerging SARS-CoV-2 variants. The study aims to generate essential real-world information on the immunogenicity and effectiveness of COVID-19 vaccines (based on inactivated virus, viral vector and others) in Indonesia in terms of immune responses, adverse reactions, and SARS-CoV-2 breakthrough infections.

Objectives:
1. To assess humoral and cellular immune responses following primer and booster vaccine doses, in individuals with and without pre-existing immunity;
2. To assess vaccine reactogenicity in individuals with and without pre-existing immunity;
3. To characterize SARS-CoV-2 breakthrough infections post-vaccination.

Importance:
The spread of the B.1.617.2 (Delta) variant threatens the success of national COVID-19 vaccine programmes, with particular concerns around the potentially reduced effectiveness of CoronaVac/SinoVac against delta infections, although it is yet unclear what will be the impact at scale. In order to address these challenges effectively, there is an urgent need to understand the biological consequences of the mutations found in these variants and the consequential impact on their susceptibility to current control measures, including vaccines, drugs and non-pharmaceutical interventions. Measuring immune correlates of vaccine–induced protection is key for understanding COVID-19 and the development of next-generation vaccines.

Advanced analytics of Covid-19 patient data to better define infection and outcomes

Principal Investigator
Dr Anuraj Shankar

Partner PI
Dr Erlina Burhan,
Faculty of Medicine
University of Indonesia;
Dr Rina Agustina,
Faculty of Medicine
University of Indonesia.

Location of activity
Jakarta, Indonesia

Collaborators
Jakarta Health Office;
National Disaster Relief Agency

Background:
Analyses of correlates of SARS-CoV-2 infection or mortality have usually assessed individual predictors. This study aimed to determine if patterns of combined predictors may better identify the risk of infection and mortality. This is a retrospective cohort study of 106 hospitalized patients. For the first nine days of the pandemic in Indonesia, we selected all 18 confirmed cases, all 60 suspected cases, and 28 putatively negative patients with pneumonia and no travel history. Hierarchical cluster analyses (HCA) and principal component analyses (PCA) identified cluster and covariance patterns for symptoms or haematology, which were analysed with other predictors of infection or mortality using logistic regression.

Importance:
For univariate analyses, no significant association with infection was seen for fever, cough, dyspnea, headache, runny nose, sore throat, gastrointestinal complaints (GIC), or haematology. A FCA symptom component for fever, cough, and GI symptoms tended to associate with increased risk of infection (OR 3.41; 95% CI 1.06–14; p=0.06), and a haematology component with elevated monocytes had decreased risk (OR 0.26; 0.07–0.79; 0.027). Multivariate analysis revealed that an HCA cluster of 3–5 symptoms, typically fever, cough, headache, runny nose, sore throat but little dyspnea and no GI symptoms, tended to reduce risk (aOR 0.048; <0.001–0.52; 0.056). In univariate analyses for death, an HCA cluster of cough, fever, and dyspnea had increased risk (OR 5.75; 1.06–31.3; 0.043). Other significant predictors of infection were age ≥ 45, international travel, contact with a Covid-19 patient, and pneumonia. Diabetes and history of contact were associated with higher mortality. Cluster groups and co-variance patterns may be stronger correlates of SARS-CoV-2 infection than individual predictors.

Outputs to date:
Evaluating clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia

Principal Investigator
Henry Surendra

Location of activity
Jakarta, Indonesia

Collaborators
Jakarta Health Office

Background:
Studies of COVID-19-related mortality in Asia, and in particular from low-resource settings, have been limited. Given that several major urban centres of Southeast Asia like Bangkok, Phnom Penh, Ho Chi Minh City, and Kuala Lumpur have thus far been spared major COVID-19 epidemics, the explosive epidemic in Jakarta can provide insights directly relevant to similar settings in other LMICs. To this end, we analysed the complete clinical and epidemiological surveillance data from the Jakarta Health Office, reporting on admissions to 55 COVID-19-designated hospitals within the city during the first five months of the epidemic (March through July 2020).

Objective:

Importance:
This retrospective hospital-based study of Jakarta’s complete epidemiological surveillance data during the first five months of the epidemic is one of the most extensive studies in LMIC and the largest in Southeast Asia to date that analysed the characteristics and outcomes of patients hospitalised with PCR-confirmed COVID-19. Overall in-hospital mortality was lower than reported in high-income countries, which is likely explained by the younger hospital population, fewer comorbidities and less severe disease. Nonetheless, age-specific mortalities were comparable to high-income countries. Although the large majority (78%) of people who died were 50 years or older, deaths occurred across all age groups. A concerning finding was the death of 11% (7/61) of children <5 years hospitalised with COVID-19, which contrasts with previous evidence that severe disease and death among children is rare. Differences in patient populations and access to quality health services, among other factors, greatly influence COVID-19 mortality trends in low-resource settings. This study affirmed the vulnerability of elderly and comorbid COVID-19 patients. Increasing burdens of non-communicable diseases in the urban centres of developing nations will impact morbidity and mortality associated with COVID-19. Further studies are needed to understand the extent and underlying causes of death related to COVID-19 in children <5 years in LMICs.

Outputs to date:
Validation of SARS-CoV-2 diagnosis with Reverse Transcription Loop-mediated Isothermal Amplification (RT–LAMP) on FTA filter paper for remote sites in Eastern Indonesia

Indonesia's island geography across more than 5000 km steeply challenges the control of the COVID-19 pandemic. Moreover, uneven laboratory diagnostic capacities in remote and sparsely populated underdeveloped eastern areas of the archipelago further complicate the problem. For example, on the eastern island of Sumba, East Nusa Tenggara, more than 30 days are required to confirm COVID-19 by RT–PCR analysis during the early months of Covid-19. The absence of RT–PCR capacity on that island forces sample delivery by now limited air transport. COVID-19 diagnostics play vital roles in support of treatment and control of SARS-CoV-2 transmission. This remarked the inequities of diagnosis that will lead to the delayed response of treatment and care for Covid-19 patients in Sumba Island and create a catastrophe of Covid-19 pandemic response in remote settings. Currently, COVID-19 RT-PCR analysis uses nasopharyngeal or oropharyngeal swab specimens as the gold standard for diagnosis. Swab collections are uncomfortable and require close interaction with patients and impose the need for specialized swabs and viral transport medium (VTM) tubes. The pandemic and this single preferred means of diagnosis have created critical supply and reagent shortages all across the globe. That already precarious supply chain is deeply exacerbated in places like eastern Indonesia, where RT–PCR capacities are nearly non-existent and technical, fiscal, and logistical limitations severely constrict access to timely COVID-19 diagnostics.

Isothermal PCR, such as loop–mediated isothermal amplification (LAMP), has been an emerging tool as a great alternative to the RT–PCR method. LAMP possesses some fundamental advantages such as amplification at a constant temperature, exclusion of a thermal cycler, a faster test result, and potentially a larger diagnostic capacity while maintaining similar sensitivity and specificity, thus making it more suitable than the RT–PCR for monitoring a pandemic.

The study aims to use RT–LAMP in the Sumba region, specifically in the Southwest Sumba district, to remedy nearly non-existent COVID-19 diagnostic services for its sensitivity, specificity, independent–logistic supply with relatively low cost per reaction ($16.5) compared to RT–PCR cost ($80 per test in Indonesia) based on our calculation. RT–LAMP platform also liberates the dependency of the supply chain by the specific vendor, so logistic supply will be under control.

Objectives:
1. Validate diagnosis of SARS-CoV-2 by analysis of saliva by RT–LAMP among patients seeking treatment for febrile illness at Southwest Sumba District, Sumba island.
2. Validate the practical diagnosis of SARS-CoV-2 by analysis of saliva specimens collected on FTA filter paper and analyzed at the RT–LAMP laboratory at Southwest Sumba.
3. Describe the prevalence of SARS-CoV-2 among patients seeking treatment for febrile illness at RSSBD (and other hospitals on the island, if necessary and practical).
4. Describe the demographic characteristics, clinical features, risk factors for severe disease, and response to treatment among patients confirmed as having COVID-19 illness.
Establishing the Southeast Asia Serological Surveillance Network (SASSNet) in Indonesia and Viet Nam

**Establishing a hospital-based nationwide sero-surveillance system in Viet Nam**

**Funder**
OUCRU (Wellcome Funding)

**Principal Investigators**
Marc Choisy
Rogier van Doorn

**Timeline:**
Started in 2009 with 10 hospitals in southern VN, expanded with 10 hospitals in northern Viet Nam in 2019, ongoing.

**Objectives:**
This project aims to establish and run a nationally representative serum bank for Viet Nam, as a resource for researchers and policymakers to understand infectious disease emergence, transmission, immunity and vaccination in the population.

**Significance:**
The platform’s strategic importance has been accentuated by COVID-19 and is as follows:

- It enhances OUCRU’s relevance to and impact upon public health in Viet Nam, supporting outbreak responses and prevention.
- It creates a substantial long-term longitudinal research resource, allowing OUCRU to address multiple research questions concerning the epidemiology of emerging and vaccine-preventable infectious diseases, but also infectious diseases for which the transmission is difficult to understand, either because part of it is not directly tractable (e.g. TB or COVID-19), or because of complex immunological processes (e.g. dengue, influenza).
- Vaccine-preventable and emerging infections, and the serum bank itself, is a part of the strategic vision for OUCRU in the applications for bridging and core funding with Wellcome.

**Output(s) to date**
Studies on influenza, tetanus and measles have been completed.

We are awaiting funding for large-scale COVID-19 research in the current and future collections to study background immunity, population-level exposure and vaccine coverage.

---

**Funder**
Not yet confirmed

**Principal Investigator**
J Kevin Baird

**Locations of activity**
Indonesia and Viet Nam

The project aims to establish the Southeast Asian Serological Surveillance Network (SASSNet) and operations in Indonesia and Viet Nam. The Network will apply optimised and validated serological sampling, analysis, and reporting of exposures to emerging and endemic neglected tropical infectious diseases of regional importance.

The project leverages both robotic ELISA and Luminex multiplex high throughput platforms in order to efficiently and sustainably surveil several dozen infections/vaccinations. The sampling strategy is a pragmatic approach of age-stratified anonymised residual blood specimens from networks of 25 hospitals in Indonesia and 20 in Viet Nam, based on existing efforts active in Viet Nam since 2009 and recently expanded throughout the entire country. The project joins academic research partners from the University of Oxford’s clinical research units in Indonesia and Viet Nam with researchers within the respective Ministry of Health in both nations.

The first year of effort focuses exclusively on serological surveillance of SARS-CoV-2 through three distinct workstreams:
1. Establishing routine national serological surveillance by ELISA;
2. Cross-sectional surveys for exposure to SARS-CoV-2 at selected sites; and
3. Following two longitudinal cohorts for serological assessment by ELISA over a 1-year period, where enrollment in one cohort immediately follows qPCR positivity for SARS-CoV-2, and in the other immediately follows vaccination against COVID-19.

Year 1 will also see the optimising and validation of a multiplex Luminex assay for six distinct SARS-CoV-2 antigenic targets and three distinct immunoglobulins (A, M, and G), along with Spike S1 and Spike N proteins of MERS-CoV, and four seasonal coronaviruses. The same multiplex assay will later include eight emerging infections (e.g. Nipah, Zika, and Japanese encephalitis viruses), neglected tropical infections (e.g., Dengue, malaria, filariasis, leprosy, and intestinal helminthiasis), and vaccine-preventable infections (e.g. measles, diphtheria, and tetanus). That multiplex serological assay will constitute the basis of routine national serological surveillance, and the project aims to build that capacity within Ministry of Health facilities in Indonesia and Viet Nam and to turn those facilities over to the respective authorities at the end of the 5-year life of the project.
Consortium for Surveillance of SARS-CoV-2 Sequence and Structure in LMICs: Leveraging the capabilities and networks of the Wellcome-funded International Units

Funder
Wellcome Trust

Principal Investigators
Philip Bejon, Le Van Tan, Anuraj Shankar

Locations of activity
Indonesia and Viet Nam

Timeline
April 2021 - April 2022

Objectives
The goal of this Consortium is to deliver large-scale real-time SARS-CoV-2 genome sequencing capacity to hospitals and local governments across Wellcome Africa-Asia programme countries. This effort, when combined with epidemiological and clinical information, will inform interventions and policy decisions during the current pandemic.

Virus genome data are combined with clinical and epidemiological datasets in order to help to guide public health interventions and policies. Subsequent analyses will enable the evaluation of novel treatments and non-pharmacological interventions on SARS-CoV-2 virus populations and spread and provide information on introductions versus community transmission and outbreaks. These data will also allow researchers to identify and evaluate emerging genetic changes and understand how they affect the ability of the virus to transmit from person to person and to cause severe forms of the disease.

Publications


Principal Investigator
SARS-CoV-2 Sequencing
OUCRU Viet Nam has dedicated our whole molecular diagnostic facilities and sample processing systems for COVID-19 diagnostics. A team of 15 senior research staff at OUCRU has teamed up with the diagnostic group at the Hospital For Tropical Diseases in Ho Chi Minh City to perform COVID-19 diagnostics.

As of July 2021, the lab can process some 1,500 tests per day. By July 5, 2021, the OUCRU/HTD diagnostics team had conducted PCR testing for 140,000 individuals in Ho Chi Minh City, Viet Nam.

We have been leading real-time whole-genome sequencing to inform Viet Nam’s outbreak response, especially in Ho Chi Minh City. The turnaround time is 24 hours. Ho Chi Minh City is one of the few places in Southeast Asia where whole-genome sequencing of SARS-CoV-2 has been successfully applied for outbreak response.

Key milestones are:
• The Tan Son Nhat international airport outbreak in February 2021. Rapid whole-genome sequencing found that the SARS-CoV-2 variant A23.1 was responsible for this outbreak. Therefore, the outbreak in Ho Chi Minh City at the time was epidemiologically unrelated to the ongoing outbreak in Hai Duong and Quang Ninh, which was caused by the Alpha variant (B.1.1.7).
• The ongoing citywide outbreak: Since the second week of May 2021, several clusters of symptomatic SARS-CoV-2 infection of unknown origin have been detected in Ho Chi Minh City. Using whole-genome sequencing, our team showed that while both the Alpha and Delta variants were responsible for these clusters, the Delta variant with higher transmissibility has become the dominant variant responsible for the current outbreak in the city.
• Collectively, these whole-genome sequencing data have been critical to informing COVID-19 response in Ho Chi Minh City and Viet Nam as a whole, contributing to the overall success of SARS-CoV-2 control in Viet Nam. We were recently recognised by the People’s Committee of Ho Chi Minh City for our contribution to the COVID-19 outbreak response in the city.

Capacity building:
We have trained our colleagues at the Institute of Pasteur in Nha Trang on the whole-genome sequencing of SARS-CoV-2. They can now operate the sequencing platform independently with remote support from our team in Ho Chi Minh City. Similarly, the team at OUCRU Hanoi has transferred sequencing protocols for direct sequencing to the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi, who are applying this independently. The OUCRU Hanoi team works with the National Hospital for Tropical Diseases and aims to sequence all epidemiologically relevant viruses weekly.
Immunogenicity and safety of COVID-19 vaccine in Vietnamese healthcare workers

Background:
According to the Viet Nam Ministry of Health, as of 4th April 2021, Viet Nam has received nearly one million doses of the AstraZeneca COVID-19 vaccine. Accordingly, a total of 52,335 frontline healthcare workers from 19 provinces/cities across the country have received their first doses. As yet, none in Viet Nam has received a second dose of the COVID-19 vaccine.

At the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, a total of 894 members of staff received their first doses of the AstraZeneca COVID-19 vaccine during the second week of March 2021. Yet, there has been no reported data regarding the immunogenicity of COVID-19 vaccines and the associated adverse events in Vietnamese people. Likewise, it remains unknown regarding the extent to which seasonal coronaviruses might interact with the immune landscape generated by the COVID-19 vaccine and vice versa.

The emergence of variants of concern (B.1.1.7, P1 and B.1.135) of SARS-CoV-2 emphasises the importance of active surveillance for SARS-CoV-2 variants worldwide. Of equal importance is to assess the immune escape potential of such novel variants. These are now the top priorities of the WHO and the public health authorities of countries across the globe.

Collectively, to inform the global vaccination programme, we aim to fill some important existing gaps in knowledge about the immunogenicity of the AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers and the adverse events that might arise within 48 hours after vaccination. More specifically, our primary aims are to determine the development of detectable neutralising antibodies after vaccination (first and second doses) and the durability of neutralising antibodies for a period of 12 months after vaccination. Additionally, to inform the public about the safety of the AstraZeneca COVID-19 vaccine, we will also synthesisedata on the associated adverse events occurring within 48 hours after vaccination. This 48-hour window time was determined by the Vietnamese Ministry of Health.

Primary Objectives:
- To determine the development of detectable neutralising antibodies to SARS-CoV-2 at 14 and 28 days after the first dose of AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers.
- To assess the durability and kinetic of neutralising antibodies against SARS-CoV-2 in Vietnamese people over 12 months after vaccination.
- To describe the adverse events arising within 48 hours after receiving the AstraZeneca COVID-19 vaccine, allied with the development of neutralising antibodies at 14 and 28 days after the first dose and 14 days after the second dose.

Secondary Objectives:
- To assess the impact of the second dose on the titers of neutralizing antibodies to SARS-CoV-2 at 14 days after the administration.
- To record SARS-CoV-2 infection events (if any) and the associated clinical features in Vietnamese people after receiving the AstraZeneca COVID-19 vaccine.
- To assess the T cell response against SARS-CoV-2 in Vietnamese people after receiving AstraZeneca COVID-19 vaccine and (if relevant) the immune escape potential of new SARS-CoV-2 variants.
- To assess the cross-reactivity between immunity induced by AstraZeneca COVID-19 vaccine and common cold coronaviruses (NL63, OC43, 229E and HKU1).

Importance:
The Africa Asia Programmes (including OUCRU) have recently been funded by Wellcome to strengthen the whole-genome sequencing capacity and to conduct active surveillance for SARS-CoV-2 variants in their respective host countries. Therefore, if relevant, we will use the collected PBMC and plasma samples of the present study to assess the immune escape potential of new variants of SARS-CoV-2.

Collectively, the present study forms a part of our holistic effort on SARS-CoV-2 evolution and immunity in Viet Nam and the region. As such, the obtained data are critical to informing the local, regional and global vaccination programme and the associated COVID-19 research.

From the public engagement perspective, it is also critical to demonstrate that the AstraZeneca COVID-19 vaccine is safe and effective. This project will provide data on the common side effects of the vaccine, and we will work with the HTD and OUCRU Public Engagement team to identify the best communication channels for this important data.

Outputs to date:
Enhancing the utility of SARS-CoV-2 antibody rapid diagnostic tests (RDTs) for disease surveillance.

**Primary objective:**
To investigate if the integration of symptomatic, demographical and diet-related comorbidities data with antibody rapid diagnostic tests (RDTs) improves their potential to assess infection rates in addition to exposure, thereby broadening their utility for surveillance.

**Importance:**
RDT-IgM/IgG-positive tests were associated with infection (OR 10.8, 95% CI 4.43 to 26.4, p<0.001) with an area under the curve (AUC) of 0.708% and 50% sensitivity, 91.5% specificity, 30.8% positive predictive value (PPV) and 96.1% negative predictive value (NPV). RDT results combined with age, gender, contact history, symptoms, and comorbidities increased the AUC to 0.787 and yielded 62.5% sensitivity, 87.0% specificity, 26.6% PPV and 96.9% NPV. SARS-CoV-2 RDT-IgM/IgG results integrated with other predictors increased test sensitivity by 25%, indicating the approach may be an affordable tool for epidemiological surveillance for population-based Covid-19 exposure and current infection, especially in groups with outbreaks or high transmission. This may provide an affordable option for surveillance as RT-PCR is sensitive but costly, and antigen-based RDTs are cheap but of low sensitivity, and both detect current infection but not exposure, but SARS-CoV-2 IgM/IgG RDTs detect exposure but with poor sensitivity for current infection.

**Output to date:**
Indonesians have suffered heavily due to COVID-19. Its causative agent, the SARS-CoV-2 virus, has been confirmed to occur in all 34 provinces. Since the first reported cases in Indonesia on 2 March 2020, nearly 250,000 cases and 9,500 deaths confirmed as COVID-19 have accrued. Both numbers are seriously under-reported as a consequence of severely limited diagnostic capacities.

We know that a heavy backlog of diagnostic services for COVID-19 pushes the turnaround time to 1-2 weeks or more, and many, if not most patients who die, do so before the diagnosis can be confirmed. Those patients are referred for burial as suspected COVID-19 and the subjects of special protocols for burial, e.g., sealed plastic wrapping rather than ritual cleansing and wrapping in fabric as per religious custom.

Given the extremely limited capacity of diagnostics, we aim to develop access to records of burials and cremations, or other measures of all-cause mortality, in these cities in order to begin to analyse the extent of mortal harm caused by COVID-19 as a means of measuring the spread and impact of SARS-CoV-2 transmission. Success in doing so would lead to broader surveys of COVID-19 attributable mortality. The protocol here represents a proposed work as a means to demonstrate the utility and validity of the methods applied.

**Objectives**

Determine quantifiable excess mortality and understanding of deaths associated with the onset of COVID-19 epidemics among eight urban centres in Indonesia. Specifically:

- Assemble weekly data on all-cause mortality by age and gender from all eight cities from January 2015 up to the present day, with weekly reporting until March 2021.
- Assemble weekly data reporting regarding COVID-19 suspect deaths, along with confirmed COVID-19 cases and confirmed deaths, all by age and gender.
- For each city, generate a monthly calculation of excess mortality attributable to COVID-19 compared to both suspected and confirmed deaths.
- Report these findings to the government agencies managing the COVID-19 crisis.

**Output to date:**

Natural history of SARS-CoV-2 in comparison to influenza A virus: a multi-site study focused in the Southern Hemisphere and equatorial regions

Aims: This study aims to conduct human surveillance for SARS-CoV-2 and influenza virus at eight sites across the Southern Hemisphere and equatorial regions. Each of these sites has an established research relationship with one of the five Centers of the CEIRS Network. Each site has the clinical and laboratory infrastructure needed to support enrollment, data and sample collection, and analysis of virological and serological parameters using qPCR and ELISA assays, respectively. Each site is furthermore able to ship biospecimens to US-based CEIRS laboratories for more in-depth analyses. One of the sites is the Ha Nam community household cohort that is led by OUCRU Hanoi and the National Institute of Hygiene and Epidemiology, Viet Nam.

Importance: Major knowledge gaps remain around the natural history of infection, the spectrum of disease, risk factors for severe outcomes and the magnitude, quality and longevity of immune responses. To address these gaps, systematic and in-depth analyses of viral load, clinical outcomes, and immune responses of infected individuals are rapidly needed. We propose to undertake such an effort. To give context to the results obtained and better understand their implications for human health, we will examine SARS-CoV-2 and influenza virus infection in parallel.

Objectives: • Document clinical outcomes and risk factors for severe disease in individuals with SARS-CoV-2 infection. • Define virology features of SARS-CoV-2 infection. • Define the magnitude, quality and longevity of immune responses to SARS-CoV-2. • Importantly, as a reference for comparison, parallel examination of influenza will be undertaken in each of these aims.

Status: The study aims to enrol 40 index cases with influenza and 40 index cases with COVID-19. We will follow-up patients in 12 months. According to the recommended schedule (10 sampling time points), acutely infected participants will be more intensively sampled to determine virus infection dynamics and kinetics, humoral and cellular immune responses, co-infections, and host gene expression.

Currently, the project is active. We are screening patients with respiratory illness in the cohort. At the time of writing, no patients have tested positive for influenza or SARS-CoV-2 viruses.

Impact of the COVID-19 epidemic on TB, HIV, and childhood vaccination programmes in Indonesia, and policy and health system factors fostering programme resilience (COHERE; COVID Health System Resilience)

As of August 18, 2021, Indonesia has the second-highest number of COVID-19 cases (nearly 3.9 million) and deaths (>120,000) in Asia and an estimated 61% excess mortality in Jakarta. Moreover, concerns have been raised around the impacts of the COVID-19 epidemic and lockdowns on the government’s health services.

However, to date, no rigorous analyses have been conducted to quantify national and district-level impacts on the care cascades for HIV, TB and childhood vaccination uptake. Based on public reports on the HIV national programme 2016–2020, we conducted preliminary analyses that suggested reductions in HIV testing, diagnosis and care cascade in the most COVID-19-affected provinces, although more complete (including 2021) and granular (weekly/monthly) data are required to draw meaningful conclusions.

This study aims to measure the impact of the COVID-19 pandemic and lockdowns on TB and HIV care cascades and childhood vaccination uptake, in Indonesia, at the national and district levels, by key risk groups. In addition, we will define the policy landscape and health system preparedness indicators that were associated with more resilient districts and further define the most vulnerable populations based on wealth, health care access, and other factors.

Objectives: 1. To measure the impact of COVID-19 on programmes for TB, HIV and childhood vaccinations in Indonesia at the national, provincial and district levels. 2. To identify policy and health system factors of resilience and key risk groups.
Strengthening Preparedness in the Asia-Pacific Region through Knowledge – SPARK

**Funder**
Australian Department of Foreign Affairs and Trade

**Principal Investigator**
Iqbal Elyazar

**Location of Activity**
Indonesia

**Website:**
www.spark.edu.au

The inter-cities mobility network plays an important role in understanding outbreaks. It serves as a proxy for the transmission network. The cities with high mobility are more vulnerable to virus infection.

Understanding the effectiveness of large-scale social distancing interventions is critical. A map that examines the impact of social distancing on population mobility will help health officials understand what policies are most effective. As governments started to introduce large-social distancing and isolation measures, we expect individuals to start adjusting their mobility behaviour. Mobility data can provide important insights into how people move and how these patterns change. This work aims to characterise people’s mobility in the high burden of SARS-CoV-2 in Jakarta, the capital of Indonesia.

**Objectives:**
1. To assess travel behaviour changes (volume and connectivity) in Greater Jakarta over time (during the large social restriction, relaxation, second large social restriction).
2. To assess how those travel behaviour changes affected the epidemic spreading in Greater Jakarta.
3. To assess how socio-economic status affected COVID-19 burden (incidence, mortality) in Greater Jakarta.

**Aims:**
The purpose of this study is to develop a mathematical model of ICU burden in time and space. The model is calibrated with data collected in Viet Nam when available or with data published from other countries (in particular, what concerns risk factors of severe cases). It takes into account age contact structure and population mobility data as inferred from the analysis of Facebook data.

**Importance:**
Such a model of ICU burden is required by the National Steering Committee for COVID-19 response. Such a model will be used to assist fast decision making if a crisis occurs. As such, the model is an original enough piece of research to be published in itself as it allows to model in great detail the distribution of the durations in the various epidemiological states. The framework of the model is generic enough to be applied to other contexts than Viet Nam and other diseases than COVID-19.

**Primary Objectives:**
1. Predict the ICU burden in space and time with and without relocation of critical equipment from hospital to hospital.
2. Look for policies (including quarantine, lock-down and stay-at-home, potentially with different implementations by locality and age class) that minimise the ICU burden using Optimal Control Theory.

**Outputs to date:**


A web-based application on contact tracing questionnaire

Funder
This project is currently seeking funding

Principal Investigators
Nhat Le, Ronald Geskus, Marc Choisy

Locations of Activity
Hanoi and Ho Chi Minh City, Viet Nam

Collaborator(s): Pham Quang Thai, Epidemiology Department, National Institute of Hygiene and Epidemiology (NIHE), Vera Arntzen (Leiden University)

Purpose:
This study aims to develop a standardised format for the questionnaire on contacts and build a smart device app to collect contact-tracing information.

Importance:
The world becomes increasingly more vulnerable to pandemics of novel infectious agents. When a novel infection emerges, an efficient methodology to contain the spread is contact tracing, which aims to identify all contacts of a diagnosed case and test them for infection.

Contact tracing is generally performed in a rush and in a way that is not always carefully considered. Furthermore, the data are collected to address immediate public health questions and are rarely collected in a standard format.

We propose a system to collect contact tracing information in a safe and standardised way. Such a system fulfills immediate public health purposes like containing the outbreak and is also helpful for research purposes. For example, contact tracing data can provide information for estimating key epidemiological quantities such as the distribution of latency and incubation period. Precise and unbiased estimates of these quantities will improve the predictions from epidemiological and mathematical models and thus are extremely valuable for efficient and timely control of the disease.

Primary Objectives:
- We design an electronic questionnaire on individual contact-tracing information, which is embedded into an app. This app connects to a central database in the cloud server. The app can also detect frequent errors during data entry, such as multiple formats of dates or Vietnamese free text. We will investigate how best to structure the questionnaires.
- We write an R package that can read the raw contact data per individual into R and transform the data into a format that consists of possible sources of infection and the period of contact with each of them. The package also includes functionalities that appeared as a shiny app that visualises the transmission chain developed by Vera Arntzen.

Outputs to date:
Pham Quang Thai, Rabaa M, Duong Huy Luong et al. The First 100 Days of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Control in Viet Nam. Clinical Infectious Diseases [Internet] 2020;72(9):e334-e342. Available from: https://doi.org/10.1093/cid/ciaa1130

The time from infection to becoming infectious (latency time) and to developing symptoms (incubation time) are key characteristics of any infection. For SARS-CoV-2, data to estimate both quantities have not been collected in a systematic way. As a consequence, information is incomplete, and there is a high risk of bias. For most individuals, the exact time of infection is not known. At most, we have information on the exposure interval during which someone became infected. Also, a large percentage of individuals remains asymptomatic, and these individuals are more likely to be missed.

Study design:
Viet Nam has performed active contact tracing of all community infected individuals and quarantined these “F1 contacts” in supervised locations. Since March 2020, all individuals that entered Viet Nam have been quarantined. In collaboration with NIHE, we combine data from different sources and outbreaks to create a unique data set with representative information on the initial stages of the SARS-CoV-2 infection and disease process.

Contact tracing data provides information on the window of exposure. For the latency time, we assume that individuals become infectious when SARS-CoV-2 RNA becomes detectable. This information is obtained from the longitudinal polymerase chain reaction (PCR) test results.

For the incubation time, we use the time when patients first report symptoms that are suggestive of SARS-CoV-2 infection; individuals that remain asymptomatic are excluded. Data on the latency time are doubly interval-censored. Not only the time origin (infection) but also the event time (detectable RNA) is at best known to lie within an interval: the presence of detectable RNA is known each time a PCR test is done. For the incubation time, we have exact information on the time of becoming symptomatic for most individuals; then, only the time origin is interval-censored. We estimate both distributions by maximising the likelihood for (doubly) interval-censored data.

Impact
The length of the quarantine period is based on estimates of the incubation time distribution because data on the latency time is lacking. Our project will fill this gap by estimating the latency time distribution. Furthermore, latency time and incubation time are important components for mathematical models that quantify and predict the spread of SARS-CoV-2.
The probability to remain asymptomatic and its dependence on age, sex and the presence of comorbidities

Many individuals that are infected with SARS-CoV-2 don’t show any symptoms. However, estimates of the probability to remain asymptomatic are scarce and likely to be biased. Data are often not collected in a systematic way, and asymptomatic individuals are more likely to be missed, creating a downward bias. One of the few exceptions is the outbreak on the Diamond Princess cruise ship in February 2020.

Study design:
Since the end of March 2020, Viet Nam has performed active contact tracing of all community infected individuals and quarantined these “F1 contacts” in supervised locations. If an F1 contact tests positive, his/her contacts become F1 contacts, etcetera. In this way, individuals within such a network of infections are unlikely to be missed.

Although some (mostly asymptomatic) infection chains may still go unnoticed, this is the closest to a representative sample of infections that can be attained. We use data from the time that contact tracing was implemented in Viet Nam.

The main source of information is the data from the Ministry of Health (MoH), but we will also use data on symptom onset after diagnosis from hospitals. Data are collected and curated by the National Institute of Hygiene and Epidemiology (NIHE).

We perform a logistic regression analysis in order to investigate how the probability of remaining asymptomatic depends on age, sex and the presence of comorbidities.

Impact:
In many countries, the state of the pandemic is monitored by testing persons with symptoms only. Knowing the proportion of individuals that remains asymptomatic helps to give a better understanding of the state of the pandemic. This holds even stronger if this information is used in a mathematical model for the spread that allows for differences in infectivity by symptomatic status. It may also be an important parameter for a model that estimates the probability of ongoing transmission, given that no symptomatic cases have been found for some period of time.

Effects of the COVID-19 pandemic on vaccine uptake in Viet Nam

Funder
Vaccine Impact Modelling Consortium

Principal Investigator
Marc Choisy (OUCRU) & Pham Quang Thai (NIHE)

Locations of Activity
OUCRU Ho Chi Minh City & NIHE (Hanoi)

Status
ongoing until November 2021

Aims:
Public health crises have collateral effects. For example, the 2014 Ebola epidemic in Western Africa severely disrupted vaccine uptakes against measles and this caused major measles outbreaks in the years that followed the Ebola crisis. Following the same rationale, we aim to assess the gaps in vaccination against childhood diseases that were caused by the COVID-19 pandemic in Vietnam in 2020 and 2021. Gaps in vaccination could be caused by imposed lockdowns during outbreaks, but also by the change in people’s behaviour between outbreaks, when people tend to avoid gathering in health centres because of the fear of getting infected.

Importance:
Vaccine-preventable diseases are both potentially extremely dangerous and, in principle, very easy to prevent as long as the vaccine coverage is high enough. By detecting the formation of “pockets of susceptibility” consecutively to the COVID-19 crisis, health authorities will be able to deploy catch-up vaccination campaigns in order to mitigate the risk of outbreaks in the most vulnerable populations.

Objectives:
• Assess the number of missed vaccinations per disease, month and province in Viet Nam;
• Assess the delays in vaccination per disease, month and province in Viet Nam;
• Convert the estimated missed and delayed vaccinations into risks of outbreak per disease, month and province in Viet Nam;
• Investigate whether there are any differences between public and private clinics.

Methods:
Analysis of the data from the national electronic vaccination registry. This system was set up in 2017 and records every single vaccine shot given to any child born after January 2017. Each record contains the vaccine given, the child ID, the day of injection, the location, as well as the type of health centre where the shot is given (private clinic versus public vaccine centre).
Optimizing the timing of the second dose of vaccine shot

Aims:
The number one goal of COVID-19 vaccines is to reduce as much as possible the risk of severe forms of COVID-19, and this objective is fulfilled by all the vaccines currently used. However, we also know that vaccines do not 100% prevent infections, and, in case of infection, they do not 100% prevent transmission either. There is more and more data that is published on the detailed within-host viral and immunological dynamics following infection or vaccination. This allows us to estimate, almost day by day, the degrees of infectiousness after infection and protection after vaccination and recovery. The aim is to develop a mathematical model based on these very detailed data, and that would account for both the within-host and between-host dynamics of the virus. This model will then be used in order to look for the optimal timing of the second dose of a vaccine. From an immunological point of view, the later the second dose is administered, the higher its efficiency. However, from an epidemiological point of view, the later the second dose is given, the more time is given to the virus to spread in the population. We will use the model to find the optimal timing that trades off these within- and between-host processes.

Importance:
Vaccination is the only way to return to normal life. The better the vaccination campaign is tuned, the sooner the return to normal life will be, and the more lives can be saved. Furthermore, there are several vaccines that are now in use, and the use of one type over another one depends essentially on the availability of each vaccine. It becomes important too to understand what are the effects of mixed vaccinations that include a first dose of one type and a second dose of another type. Finally, it has also been proposed that giving half a dose to twice as many people could be an efficient strategy at the epidemiological level.

Objectives:
• Is it better to vaccinate twice as many people with one dose or twice as fewer people with two doses. The answer likely depends on the types of vaccine and the exact epidemiological situation.
• Same questions with half a dose.
• What is the optimal timing of the second dose? The answer likely depends on the types of vaccine and the exact epidemiological situation.

Evaluating mortality data to capture the dynamics of COVID-19 in Java, Indonesia

Background
As in many countries, quantifying COVID-19 spread in Indonesia remains challenging due to testing limitations. In Java, non-pharmaceutical interventions (NPIs) were implemented throughout 2020. However, as a vaccination campaign launches, cases and deaths are rising across the island.

We used modelling to explore the extent to which data on burials in Jakarta using strict COVID-19 protocols (C19P) provide additional insight into the transmissibility of the disease, epidemic trajectory, and the impact of NPIs. We assess how the implementation of NPIs in early 2021 will shape the epidemic during the period of likely vaccine rollout.

Objectives
1. To explore the extent to which data on burials in Jakarta using strict COVID-19 protocols (C19P) provide additional insight into the transmissibility of the disease, epidemic trajectory, and the impact of NPIs.
2. To assess how the implementation of NPIs in early 2021 will shape the epidemic during the period of likely vaccine rollout.

Importance
COVID-19 protocols burial data in Jakarta suggest a death toll approximately 3.3 times higher than reported. Transmission estimates using these data suggest earlier, larger, and more sustained impact of NPIs. Measures to reduce sub-national spread, particularly during Ramadan, substantially mitigated spread to more vulnerable rural areas. Given the current trajectory, daily cases and deaths are likely to increase in most regions as the vaccine is rolled out. Transmission may peak in early 2021 in Jakarta if current levels of control are maintained. However, relaxation of control measures is likely to lead to a subsequent resurgence in the absence of an effective vaccination campaign. Syndromic measures of mortality provide a complete picture of COVID-19 severity upon which to base decision-making. The high potential impact of the vaccine in Java is attributable to reductions in transmission to date and is dependent on these being maintained. Increases in control in the relatively short-term will likely yield large, synergistic increases in vaccine impact.

Outputs to date:
COVID-19 Social Science and Public Engagement Action Research in Viet Nam, Indonesia and Nepal (SPEAR)

Funder:
OUCRU
(Wellcome funding)

Principal Investigators:
Jennifer Van Nuil,
Sonia Lewycka,
Mary Chambers,
Abhilasha Karkey,
Raph Harriers

Phase 1: Exploring the experiences and impacts of COVID-19 for healthcare workers and vulnerable communities

Aims:
This project draws on anthropological and participatory engagement methods to explore the wider socio-cultural context of COVID-19 and its impact on health-related workers and vulnerable communities in Viet Nam, Nepal, and Indonesia.

Primary Objectives:
- Identify and describe the experiences and perceptions of healthcare workers and other healthcare staff during/after the COVID-19 pandemic in Nepal, Indonesia, and Viet Nam.
- Explore the impact of the COVID-19 outbreak on vulnerable communities in Nepal, Indonesia, and Viet Nam.
- Identify misinformation circulating within these populations and co-design targeted evidenced-based public engagement.

Phase 1 progress:
To date, in June 2021, we have collected almost 4,000 surveys, 222 in-depth interviews, and 59 digital diaries across the sites, including participants from both healthcare workers and community members groups.

Photo:
Sarita Pyatha,
Digital Diary participant,
Hospital Lab Worker,
Kathmandu, Nepal.
Kathmandu International Film Festival
Digital diaries:
http://www.oucru.org/digital-diary/

Media monitoring:
http://www.oucru.org/media-monitoring/

Phase 2: Exploring barriers to access and uptake of SARS-CoV-2 vaccines in Viet Nam, Indonesia and Nepal to inform national vaccine strategies

Aims:
To inform national policy and support initiatives to ensure equitable access to SARS-CoV-2 vaccines and effective public engagement through exploration of public perceptions and understanding.

Primary Objectives:
To inform national and global policymakers concerning access and acceptance of COVID–19 vaccines.

It is intended that the project will provide evidence to:
• Enable us to create targeted evidence-based public health information to counter misinformation;
• Enable partner and government organisations to strengthen their support for health workers and improve the access of vulnerable communities to public health measures;
• Contribute to global discussions and guidelines (e.g. WHO facilitated forums) about ethics, public engagement and COVID–19, and support for healthcare workers.

Phase 2 progress:
We expanded SPEAR to include additional data collection (surveys and in-depth interviews) focused on vaccine acceptance and access within the study sites. The second phase of SPEAR will start by August 2021.

Project progress:
The SPEAR teams are embedded in multiple sites within Viet Nam, Nepal, and Indonesia, with both social science data collection and engagement activities taking place within each site. These methods include surveys, focus groups discussions, interviews, ‘digital diaries’ (filming of personal stories), and online forums. In addition, we have a Media Monitoring component to track the misinformation that is circulating online about Covid–19.

Outputs to date:

SPEAR in Viet Nam
The SPEAR project in Viet Nam is being led by Jennifer Ilo Van Nui and Sonia Lewycka for the social science components and Mary Chambers for the public engagement component, with project management support from Joam Fisher. There are four main sites in Viet Nam, including the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, National Hospital for Tropical Diseases in Hanoi, and areas with ongoing research collaborations in Nam Dinh and Dak Lak.

OUCRU’s social science data collection team working in HCMC includes Nguyen Thi Hong Yen, Nguyen Thi Kim Ngoc, Nguyen Le Thao My, Tran Kim Minh Hien, Nguyen Hoang Yen, Tran Kim Van Anh, and Hung Vu Bao, Nguyen Thanh Phong, and Pham Ngoc Thanh together with collaborators from the HTD hospital including Dr Nguyen Thanh Phong, Dr Nguyen Thanh Truong, and Head Nurse Bui Thi Hong Ngoc.

The team in Nam Dinh and Hanoi includes Yen Nguyen Thi Hong, Nam Vinh Nguyen, Tran Phuong Thao, Nguyen Thi Kim Tuyen, and Tran Thi Hang, along with collaborators from National Hospital for Tropical Diseases. The Dak Lak team includes Nguyen Thanh Ha, and Nguyen Le Thao My. Nguyen Hoang Yen coordinates the digital diary engagement data collection within Viet Nam.

SPEAR in Nepal
The SPEAR project in Nepal under the supervision of Abhilasha Karkey is being coordinated by Samita Rijal (social sciences research) and Summita Udhas (public and community engagement). Dinesh Deokota is leading the Digital Diary component for the whole project, and in Nepal, and leading recruitment for the community-based research.

The social science research team includes Samita Rijal, Summita Udhas, Dr Amit Gautum, Aakriti Pandey, and Pratibha Thapa. The psychology team for the study includes Dr Rabi Shyaka, Dr Pawan Sharma, and Anup Rajbhandari, all senior practising psychiatrists at the Patan Hospital.

The study is being conducted in 4 regions: Kapilbvastu/Biratnagar/Dharan, Urban region (Kathmandu/Bhaktapur/Patan), Hills region (Sindhulpalchowk), Mountainous region (lower Mustang).

SPEAR in Indonesia
The SPEAR project in Indonesia is being led by Dr Dewi Friska, from the Faculty of Medicine, Universitas Indonesia and Dr Raph Hamers (EOCRU). The project is being coordinated by Ragil Dien and Mutia Rahardjani from EOCRU, and advised by Dr Aria Kekalih, from the Department of Community Medicine, Universitas Indonesia.

The EOCRU social science research and public engagement team include: Ragil Dien, Livia Nathania Kurniawan, Ida Ayu Sutrisni, Ralalicia Limato, and Diana Timoria, Collaborations are with local hospitals and Puskesmas in Jakarta and Bandung and The Sumba Foundation in Sumba. The study is being conducted in three provinces: DKI Jakarta, West Java, and Nusa Tenggara Timur (NTT).
PUBLIC & COMMUNITY ENGAGEMENT

Public and community engagement response to Covid-19

Funder: OUCRU (Wellcome funding)
Principal Investigator: Mary Chambers
Location of activity: Viet Nam, Indonesia and Nepal

Objectives
Building trust in a time of public health crisis through public and community engagement, including:
- Building dialogue between public and experts;
- Listening to communities;
- Empowering communities through knowledge transfer;

Photo: Workshops for young people exploring the avenues through which news is disseminated and developing skills for assessing the strength of the news being shared. Viet Nam.

Photo: Digital diary participants from West Sumba, Eastern Indonesia

Photo: Pexels/Rebecca Zaal
Public and community engagement response to Covid-19

Outputs to date

**Dialogue | 2020**

- ‘Online science debates’ - engaging Vietnamese young people and scientists to use debate as a tool for discussing health science-related topics. Viet Nam.
- ‘Ask the Scientists’ – OUCRU Schools Engagement team. Online ‘chats’ between schoolchildren and scientists. Viet Nam.
- ‘Science against fake news’ Ho Chi Minh City, June 26, 2020– equipping junior students with skills to recognise fake news.
- ‘Combating Covid–19 related fake news’, Ho Chi Minh City, July 25, 2020 – improving health literacy for young people (Facilitated by Media and Communication Officer. University of Social Science and Humanities)

**Dialogue | 2021**

- Digital Diaries Video Screening at OUCRU (7th March 2021) and with Medical Doctors at Teaching hospital (March 30, 2021) Nepal.
- Virtual Tea Talks Series with OUCRU staff - In collaboration with the Patan Hospital psychiatric department, a series of programs to address mental health issues in the workplace: Tea talks (informal program) aimed at helping to reduce stress and sharing experiences, walk-in counselling sessions (formal support). May - June 2021, Nepal.

**Public & Community Engagement**

**Covid-19 Research and Engagement Projects Portfolio | August 2021**
Public and community engagement response to Covid–19

Outputs to date (cont.)

Listening to communities | 2020
- Schools Photo Competition – Photo and caption about the learning experience in Covid–19 lockdown in Viet Nam.
- Advisory group meeting: HTD healthcare workers. June 10, 2020; Viet Nam.

Listening to communities | 2021
- ‘Voice of science’ - a digital youth engagement platform to put science at the heart of Vietnamese young people as well as to collect their perspectives and recommendations for good health research activities. Viet Nam.
- Digital Diaries (personal stories of Covid–19 experiences): Viet Nam, Nepal and Indonesia
  - https://www.instagram.com/storiesfromtheislands/

Knowledge transfer | 2020
- Articles for The Conversation newspaper - EOCRU – Indonesia.
- Poster ‘How to protect yourself from Covid–19’ - OUCRU NP - Nepal.
- WHO ‘Myth Busters’ for social media – in Vietnamese and Nepali OUCRU & OUCRU NP.
- Khan Quang Do (Youth Magazine) Articles, Viet Nam, on the following topics:
  - Emotion Trap in Consuming News in the Pandemic September 8, 2020; Viet Nam.
  - Nutrition Misunderstanding in the Pandemic Context, September 15, 2020; Viet Nam.
  - Four unknowns about Covid–19, September 29, 2020; Viet Nam.
  - What is the smallest living organism in the world? October 6, 2020; Viet Nam.
  - Wildlife Consumption, October 13, 2020; Viet Nam.

Knowledge transfer | 2021
- Podcast program. (7 episodes – November 2020 – current): A monthly podcast on Spotify aimed at accurate public health communication. Involving doctors, researchers, EOCRU experts in medical, public health, and related fields as well as external speakers (Dr Siti Nadia, M. Epid (Spokesperson for Covid–19 Vaccination from Indonesia’s Ministry of Health) and Prof Zubairi Djobran, Sp.PD-KHOM (Head of the Covid–19 Task Force of The Board of the Indonesian Medical Association/Pengurus Besar Ikatn Dokter Indonesia). Indonesia.
- Radio program (Sumba) – Aiming to disseminate significant and accurate information and engage interest in health issues amongst the public in rural areas in Sumba. Using easy-to-understand language in the local dialect, the program is aired on bi-weekly basis and has released four episodes. Indonesia.
- Covid-19 Related Video Interview Series (EOCRU Social Media), Indonesia. To engage and educate the public through social media about the Covid-19 pandemic, we created a series of 6 videos of interviews with 4 internal researchers and collaborators, on the following topics:
  - Future of Covid–19 in Indonesia through mathematical modelling;
  - Covid–19 herd immunity in Indonesia: What, when, and how;
  - How effective are large-scale social restrictions and mudik (returning to hometowns) prohibitions to suppress the number of cases and the transmission rate of Covid–19 in Indonesia?;
  - The impact of mass media publication about Covid–19 toward public decision and action;
  - How we can be more careful in consuming Covid–19 related news.
- ‘Digital science hub’ – a joint project between OUCRU and Bayer Viet Nam to develop the science literacy of Vietnamese children through online engagement and science learning activities. Viet Nam.
- World Immunization Week: ‘I’m vaccinated’ social media campaign Viet Nam.
- Short film for social media: ‘Q & A on Covid–19 Vaccine’ – Hospital for Tropical Diseases HCMC with Dr Truong Ngoc Trung. Viet Nam.
- Poster – Post-vaccination advice, displayed in the hospital and the community. Nepal.
Combating Covid-19-related disinformation and fake news

**Importance:**
Public health and wellbeing is put at risk by disinformation and fake news, and never more seriously than in times of public health emergencies such as the current Covid-19 pandemic. While traditional news remains a dominant source of scientific information, social media platforms have become important sources of health information and sites for public discourse. However, the health and science presented on these platforms are often problematic. We propose that the antidote to this risk is a targeted and positive public engagement response delivering evidence-based news in partnership with policymakers and key public health stakeholders.

**Methods:**
By tracking current disinformation and fake news stories about Covid-19 and the Covid-19 vaccines on social media in Viet Nam, Nepal and Indonesia – the host countries for Oxford University Clinical Research Units, we will identify misinformation that is circulating in these communities. Our findings will be fed back to national policymakers and public health stakeholders to enable them to tailor their Covid-19 related public health messaging. We will bring working groups together to develop evidence-based, locally appropriate public engagement media and open discussion forums to positively counter the trending misinformation, thereby increasing understanding, safe behaviour and public/expert trust.

**Outputs to date:**
- **Workshops:**
  - Media literacy workshops for young people – developing tools to recognize fake news on social media and online media (2020), Viet Nam;
  - Science Against Fake News Workshop for high school students to equip with skills of analysis and evaluation of information on the Internet (2020), Viet Nam;
- **Online discussions:**
  - ‘The health of pregnant and breastfeeding mothers during the pandemic’. Instagram Livestream discussion (6 August 2021), Indonesia.
- **Online engagement:**
  - Social media: Facebook and Instagram animations and health education materials to counter identified misinformation content within the media about Covid19 and Covid19 vaccines. e.g. Myth busters (2020), Viet Nam; #Iamvaccinated campaign (2021), Viet Nam;
  - Viber: Q & A of specific health information to community disseminated via community health worker Viber networks (2021), Nepal;
  - Podcasts: Monthly podcast with medical and scientific experts providing accurate health information (November 2020 – current), Indonesia;
- **Youtube videos:**
  - Coping with stress during the COVID-19 pandemic’ (April 21, 2020), Indonesia. Available at: youtu.be/9FodSAYpI4A
  - How to quarantine F0 at home’ (August 10, 2021), Viet Nam. Available at: youtu.be/4dP770XaCi4
  - Answering questions about the Covid-19 Vaccine with Dr Truong Ngoc Trung (HTD) (May 2021), Viet Nam. Available at: youtu.be/t3xGkqTHSuw

---

**Funder**
University of Oxford

**Principal Investigator**
Mary Chambers

**Collaborators**
Nguyen Thanh Ha, Tran Minh Hien, Summita Udas, Ragil Dien, Livia Nathania Kurniawan, Katrina Lawson

**Location of activity**
Ho Chi Minh City, Viet Nam; Jakarta, Indonesia

---

**Photo:**
Covid-19 and the Gendered Research Gap

Among the many extraordinary responses to the COVID-19 pandemic globally, has been the response in the research community, with thousands of new collaborations, projects and publications being rapidly developed and implemented. These have been supported by funding schemes, many of which have been modified or expanded. While these initiatives have led to breakthroughs in COVID-19 prevention, treatment and control, the gendered impacts on the health and medical research workforce cannot be ignored.

Early in the pandemic, transition to home working, and innovations such as online meetings were hailed as breakthroughs in research culture, addressing many of the barriers female scientists had experienced to progressing careers. However, as women still hold the majority of primary caring roles globally, the shift to working from home, coupled with school closures, left many women juggling caring and career responsibilities. Studies conducted since early in the pandemic have demonstrated that women are underrepresented in journal submissions and publications. How this may impact women’s long-term careers is unknown, although journal publications remain key academic outputs and prerequisites for future funding.

The OUCRU Women in Science Group is collaborating with the George Institute in Australia, and NAFOSTED in Vietnam to explore these issues more deeply. Initial findings from looking at publicly available data in Australia, the UK and Vietnam have shown that inequitable distribution of research funding impacts the feasibility and sustainability of women in health and medical research careers. Work needs to be done to assess and address factors contributing to this, to ensure that the gendered gaps don’t continue to widen as the pandemic progresses.
Engaging with policymakers in the COVID-19 pandemic through the creation of an Outbreak Advisory Board

In order to ensure that OUCRU’s COVID-19 research is locally-driven and is best able to achieve local, regional and global impact, we have established an OUCRU Outbreak Advisory Board (OAB).

The goals of the OAB are to:
- Provide a forum to discuss, share and understand activities and priorities in the context of infectious disease outbreaks.
- Ensure that OUCRU’s outbreak response projects are useful for key stakeholders’ policy needs.
- Strengthen the networks between researchers and policymakers focused on outbreak response at national and international levels.

Board members come from multiple levels in the Vietnamese COVID-19 response: national and regional, domestic and international – to ensure broad perspectives are included. The OAB was established in response to COVID-19 but will exist in perpetuity and in future will be able to advise on work relating to general epidemic preparedness and acute outbreaks.

During the pandemic, the board convenes quarterly, using Zoom. Meetings are short, structured and planned in advance. To date, two meetings have been conducted, one in October 2020 and another in March 2021. The third meeting, which should have been organised in June, was cancelled due to the complicated situation of the outbreak happening nationwide. This meeting will be rescheduled as soon as practical. The first meeting focused on understanding each member’s concerns and their activities related to COVID-19 while the second meeting was specific to vaccination strategies, post-vaccination immunology and testing strategies. Establishing the OAB had its challenges, but once set up, it is easy to maintain, and serves as a forum for researchers and policymakers to connect regularly across a wide range of interest areas.

Summary of Covid-19 press outputs

The Covid-19 pandemic has elevated OUCRU’s position as an expert in infectious diseases. Because of our involvement in various Covid-19 projects and our works in supporting governments to manage Covid-19 outbreaks in Viet Nam, Indonesia, and Nepal, we have received a substantial volume of interview requests and press mentions.

More specifically:

From July 1, 2020, to June 30, 2021, OUCRU has received a total of 54 interview requests, including nine requests from Vietnamese publications and 45 requests from international news networks.

Our experts have given 30 interviews with prominent news outlets and networks, including the Associated Press, Business Insider, BBC News, The Economist, ChannelNewsAsia, Le Figaro, and Vietnamese publications such as VTV News, VNExpress, Zing News, VTC News, etc.

These interviews have been cited 76 times in 24 English publications and 52 Vietnamese publications.

The issues mentioned can be divided into three large categories:
1. Management of Covid-19 outbreaks in Viet Nam;
2. OUCRU’s works in sequencing the SARS-CoV-2 virus;

The full list of articles is available upon request.
In collaboration with:

- Professor, Mahidol University, Thailand
- Director, Hospital For Tropical Diseases, Ho Chi Minh City, Viet Nam
- Director, National Hospital for Tropical Disease, Hanoi, Viet Nam
- Director, Wellcome-KEMRI-Oxford Collaborative Research Programme, Kenya
- Deputy Head, Epidemiology Department, Viet Nam NIHE
- PhD Candidate, Leiden University, the Netherlands
- Professor, Leiden University, the Netherlands
- Post-doctoral Scientist, MIVEGEC, CNRS-IRD-University of Montpellier, France
- Research Scientist, MIVEGEC, CNRS-IRD-University of Montpellier, France
- Director of Research, MIVEGEC, CNRS-IRD-University of Montpellier, France
- Lecturer, Department of Community Medicine, Universitas Indonesia
- Lecturer, Department of Community Medicine, Universitas Indonesia
- Health Program Director, The Sumba Foundation, Indonesia
- Director, Media for Development, Nepal
- Senior Practicing Psychiatrist, Patan Hospital
- Senior Practicing Psychiatrist, Patan Hospital
- Director, Hospital For Tropical Diseases, Ho Chi Minh City, Viet Nam
- Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
- Head Nurse, Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam
- Dak Lak CDC
- Dean, Faculty of Medicine University of Indonesia
- Director, Indonesia Medical Education and Research Institute
- Lecturer, Faculty of Medicine University of Indonesia
- Vice Dean Faculty of Medicine University of Indonesia
- Head, Human Nutrition Research Center, Indonesia Medical Education and
  Research Institute, Faculty of Medicine University of Indonesia
- Anaesthesiologist, Fatmawati Hospital
- Infectious Disease Physician, Pelni Hospital
- Pathology Specialist, Pasar Minggu Hospital
- Lecturer, Faculty of Medicine, University of Sumatera Utara
- Director of Murni Teguh Hospital
- Director of Bunda Thamrin Hospital
- Lecturer, Faculty of Medicine Universitas Airlangga
- Infectious Disease Physician, Adam Malik Hospital
- Infectious Disease Physician, Sardjito Hospital
- Infectious Disease Physician, Hasan Sadikin Hospital

Director
Director of OUCRU Ha Noi
Director of EOCRU
Director of OUCRU Nepal

Dr Claus Bogh
Bonifacius
Yohanes Niko Santoso P.
Yacobus B. Da Costa
Assoc. Prof. C Louise Thwaites
Assoc. Prof. Ronald Geskus
Dr Marc Choisy
Dr Le Thanh Hoang Nhat
Dr. Du Hong Duc
Dr. Phung Khanh Lam
Dr. Thomas Kesteman
Dr Nguyen Thi Tam
Trinh Son Tung
Ong Phuc Thinh
Tran Thi Bich Lieu
Duong Thuy Trang
Nguyen Duc Manh
Nguyen Thi Minh Nguyen
Dr Jennifer Van Nuil
Dr Sonia Lewycka
Evelyne Kestelyn
Dr Celine Pascale Vidaillac
Dr Nguyen Thi Phuong Dung
Dr Nguyen Than Ha Quyen
Nguyen Bao Tran
Nguyen Thi Huyen Trang
Dr Mary Chambers
Jaqueline Fish
Nguyen Thi Hong Yen
Nguyen Le Thao My
Nguyen Van Vinh
Nguyen Thanh Ha
Nguyen Thi Kim Ngoc
Tran Minh Hien
Nguyen Hoang Yen
Tran Dong Thai Han
Tran Kim Van Anh
Pham Ngoc Thanh
Doan Phuong Nhung
Nguyen Van Vinh

Dr Erfina Burhan
Director of the Sumba Foundation
Physician, Karitas Hospital
Director, Karitas Hospital
Pratama Rada Bolo Hospital
Summit Institute for Development
Summit Institute for Development
Lecturer, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital

OUCRU
Dr Sophie Yacoub
Prof Jeremy Day
Dr Le Van Tan
Assoc. Prof. C Louise Thwaites
Assoc. Prof. Ronald Geskus
Dr Marc Choisy
Dr Le Thanh Hoang Nhat
Dr. Du Hong Duc
Dr. Phung Khanh Lam
Dr. Thomas Kesteman
Dr Nguyen Thi Tam
Trinh Son Tung
Ong Phuc Thinh
Tran Thi Bich Lieu
Duong Thuy Trang
Nguyen Duc Manh
Nguyen Thi Minh Nguyen
Dr Jennifer Van Nuil
Dr Sonia Lewycka
Evelyne Kestelyn
Dr Celine Pascale Vidaillac
Dr Nguyen Thi Phuong Dung
Dr Nguyen Than Ha Quyen
Nguyen Bao Tran
Nguyen Thi Huyen Trang
Dr Mary Chambers
Jaqueline Fish
Nguyen Thi Hong Yen
Nguyen Le Thao My
Nguyen Van Vinh
Nguyen Thanh Ha
Nguyen Thi Kim Ngoc
Tran Minh Hien
Nguyen Hoang Yen
Tran Dong Thai Han
Tran Kim Van Anh
Pham Ngoc Thanh
Doan Phuong Nhung
Nguyen Van Vinh
References

12. Larkins et al. Impact of the pandemic on Australia’s research workforce. Australian Academy of Science 2020